Aspen HIV Prevention Pill Deal Expands African Access

Original Article by Tamar Kahn | Business Day | 27 July 2026

Aspen HIV prevention pill licensing deal positions the SA manufacturer to supply lower-cost monthly PrEP across key African markets.

Aspen HIV Prevention Pill Deal Expands African Access

Image | Gam1983 | iStock/1181839849

Aspen Pharmacare will become a major African supplier of Merck’s experimental monthly HIV prevention pill, alimatravir. The agreement depends on the medicine successfully completing clinical trials and receiving regulatory approval.

Merck granted voluntary licenses to seven generic drug manufacturers, including the South African company, to produce and distribute lower-cost versions of the medicine. The drug also goes by its development code, MK-8527.

Merck’s royalty-free agreements cover 129 low- and lower-middle-income countries. Licensed manufacturers will be able to supply patients in both the public and private healthcare sectors.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here

More Posts

Extensior Launch Cuts Ozempic Cost By 15%

The Extensior launch in South Africa offers 15% lower semaglutide prices, but Discovery Health says scheme coverage is unlikely to expand.

Read more...

Generic Drug Tariffs Could Raise US Medicine Costs

Generic drug tariffs could raise US medicine costs, disrupt global supply chains and pressure manufacturers to move production to America.

Read more...

Medicine Safety Under Scrutiny after iDexis Case

Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring.

Read more...